Skip to main content

Table 2 Description of the sample

From: Cost-effectiveness analysis of a randomized study of depression treatment options in primary care suggests stepped-care treatment may have economic benefits

All participants

 

SC (n = 412)§

TAU (n = 397)

ICBT (n = 415)

SCP (n = 183)

All (n = 1407)

Age (s.d.)

46.9 (17.1)

45.5 (16.3)

46.6 (16.8)

52.3 (17.6)

47.1 (17.0)

Female (%)

75%

78%

70%

61%

73%

PHQ-9 (s.d.), baseline

4.55 (4.95)

4.98 (5.19)

4.2 (4.61)

4.86 (5.54)

4.61 (5.01)

PHQ-9 (s.d.), 12-week

3.85 (2.94)

4.12 (3.09)

3.65 (2.74)

4.04 (3.29)

3.89 (2.98)

within group difference (95% CI)*

0.69 (0.50 to 0.98)

0.88 (0.67 to 1.08)

0.55 (0.37 to 0.73)

0.82 (0.49 to 1.15)

0.72 (0.61 to 0.82)

EQ-5D-5 L (s.d.), baseline

0.86 (0.11)

0.84 (0.14)

0.86 (0.12)

0.86 (0.13)

0.86 (0.12)

EQ-5D-5 L (s.d.), 12-week

0.88 (0.06)

0.87 (0.08)

0.88 (0.07)

0.88 (0.08)

0.88 (0.07)

within group difference (95% CI)**

0.022 (0.017 to 0.026)

0.03 (0.024 to 0.035)

0.022 (0.017 to 0.027)

0.022 (0.014 to 0.03)

0.024 (0.021 to 0.027)

Depressed participants (PHQ-9 > 10 at baseline)

 

SC (n = 56)

TAU (n = 66)

ICBT (n = 50)

SCP (n = 34)

All (n = 206)

Age (s.d.)

44.7 (16.3)

44.8 (14.2)

42.2 (13.8)

49.0 (16.4)

44.8 (15.1)

Female (%)

80%

70%

70%

74%

74%

PHQ-9 (s.d.), baseline

14.73 (4.17)

14.83 (3.91)

14.28 (3.76)

14.85 (3.84)

14.67 (3.91)

PHQ-9 (s.d.), 12-week

9.9 (2.48)

9.94 (2.31)

9.64 (2.24)

9.98 (2.28)

9.86 (2.32)

within group difference (95% CI)*

4.83 (4.37 to 5.28)

4.85 (4.46 to 5.24)

4.64 (4.21 to 5.08)

4.88 (4.33 to 5.42)

4.8 (4.58 to 5.02)

EQ-5D-5 L (s.d.), baseline

0.68 (0.18)

0.63 (0.2)

0.67 (0.22)

0.68 (0.21)

0.66 (0.2)

EQ-5D-5 L (s.d.), 12-week

0.78 (0.1)

0.74 (0.12)

0.77 (0.13)

0.78 (0.12)

0.76 (0.12)

within group difference (95% CI)**

0.095 (0.075 to 0.115)

0.118 (0.096 to 0.139)

0.1 (0.075 to 0.126)

0.094 (0.064 to 0.125)

0.103 (0.092 to 0.115)

  1. §: This table represents numbers of patients at baseline. Patient numbers at 12-week are available in the Additional file 1
  2. *: There was significant improvement between baseline and 12-week post-randomization (p = 0.015 for SC, 0.004 for TAU, 0.037 for ICBT, and 0.086 for SCP in all participants and < 0.001 in depressed participants). There was no statistically significant difference between groups at baseline and 12 weeks (p > 0.1 in all participants including depressed participants)
  3. **: There was significant improvement in EQ-5D-5 L scores between baseline and 12-week post-randomization (p < 0.001 for SC, < 0.001 for TAU, 0.002 for ICBT, and 0.066 for SCP in all participants and p < 0.002 for SC, < 0.001 for TAU, < 0.007 for ICBT, and 0.033 for SCP in depressed participants). All pairwise differences of the means among the intervention arms were not statistically significant (p > 0.5)
Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us